HeartLung Corporation's AI-CVD platform receives FDA clearance to detect multiple diseases from a single CT scan.
Key Details
- 1AI-CVD is cleared via FDA 510(k) by HeartLung Corporation.
- 2The platform analyzes CT images of the chest and abdomen to screen for various diseases.
- 3No additional CT sequences, radiation, or contrast are needed to use the tool.
- 4Automatically quantifies clinical measurements for cardiovascular and non-cardiovascular conditions.
- 5Diseases targeted include coronary artery disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, and diabetes.
Why It Matters
The clearance marks a significant step for opportunistic AI in radiology, enabling wider disease detection from standard CT scans without extra imaging, doses, or disruptions. This has the potential to improve early diagnosis and make radiology workflows more efficient.
Source
Radiology Business
Related News
•AuntMinnie
Study: Computer Vision Models Best LLMs in Chest CT Breast Abnormality Detection
Computer vision models (CVMs) surpass large language models (LLMs) in accurately labeling incidental breast abnormalities on chest CT scans.
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.
•Cardiovascular Business
Radiology Maintains Lead in FDA-Cleared AI Algorithms, Cardiology Follows
Radiology remains the top specialty for FDA-cleared AI, with cardiology as a strong second, particularly in cardiovascular imaging.